Nicotine Addiction Clinical Trial
Official title:
Nicotine Reinforcement and Aversion in Young Adult Light Smokers
Verified date | August 2021 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The proposed study will examine the threshold for nicotine self-administration (NSA) using five different nicotine doses in young adult male and female non-dependent smokers (light and intermittent smokers or LITS). We propose a double-blind, placebo-controlled study that will enroll 195 individuals, targeting a total of 72 completers (36 male and 36 females). In each of the five experimental sessions, smokers will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.05, 0.1 and 0.2 mg/70 kg). The highest dose, 0.2 mg/70 kg, corresponds to nicotine delivered by about one or two puffs of a cigarette. At the beginning of each experimental session, smokers will sample the assigned both the nicotine dose for that experimental session, and the placebo (saline) dose, followed by the opportunity to choose between nicotine and placebo for a total of ten choices over a 150-minute period. The main outcomes will be threshold dose (the minimum dose of nicotine that is self-administered more than placebo) and the slope of dose-response for nicotine self-administration (changes in nicotine self-administration per unit change in nicotine dose). We will also collect measures of nicotine intake (cotinine), nicotine clearance (3-hydroxycotinine (3-HC) / cotinine), and self-report drug effects
Status | Completed |
Enrollment | 34 |
Est. completion date | March 31, 2020 |
Est. primary completion date | March 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 30 Years |
Eligibility | Inclusion criteria: 1) Female and male smokers, aged 18 to30 years, who have been smoking for at least a year, and a life-time consumption of at least 100 cigarettes; 2) smoke more frequently than once a week and =5 cpd; 3) FTND score <3 indicating no or minimal evidence for nicotine dependence; 4) urine cotinine levels >100 ng/mL indicating smoking status and a level <1000 mg/mL consistent with nicotine intake of LITS; 5) not seeking treatment at the time of the study for nicotine dependence; 6) in good health as verified by medical history, screening examination, and screening laboratory tests; 7) for women, not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods. Exclusion criteria: 1) history of major medical illnesses that the physician investigator deems as contraindicated for the subject to be in the study; 2) requirement of any form of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics) or psychiatric diagnosis and treatment for psychiatric disorders including major depression, bipolar disorder, schizophrenia in the past 6 months; and 3) current dependence to alcohol or any other recreational or prescription drugs and; 4) daily use of smokeless tobacco products or exclusive daily use of e-cigarettes (non-daily users will be included). |
Country | Name | City | State |
---|---|---|---|
United States | Department of Veterans Affairs | West Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | DEQ - Pleasurable | The Drug Effects Questionnaire (DEQ) ratings subscale that measures the pleasurable effects was used. I The minimum score is zero with the maximum score of a 100millimeters.
The higher the score means the more pleasurable. |
Up to 10 Minutes | |
Primary | DEQ - Aversive | The DEQ is measured using millimeters. The minimum score is zero with the maximum score of a 100millimeters. rug Effects Questionnaire (DEQ) ratings subscale that measures the aversive effects was used. The higher the score means more aversive. | Up to 10 Minutes | |
Primary | DEQ - Stimulatory | The Drug Effects Questionnaire (DEQ) ratings subscale that measures the stimulatory effects was used.
DEQ is measured using millimeters. The minimum score is zero with the maximum score of a 100millimeters. The higher the score means more stimulation. |
Up to10 Minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02643914 -
Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings
|
N/A | |
Completed |
NCT02153749 -
Effects of Brief Training on Craving Regulation
|
N/A | |
Recruiting |
NCT05530577 -
Effects of Semaglutide on Nicotine Intake
|
Phase 2 | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A | |
Completed |
NCT03694327 -
Innovative Digital Therapeutic for Smoking Cessation
|
N/A | |
Completed |
NCT01944423 -
Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
|
Early Phase 1 | |
Completed |
NCT01704573 -
Nicotinic Receptor Levels After Stopping Smoking
|
N/A | |
Active, not recruiting |
NCT01015170 -
STOP Study: Effectiveness of Zyban in a Clinical Population
|
Phase 4 | |
Completed |
NCT03281629 -
Circuitry-Guided Smoking Cessation in Schizophrenia
|
N/A | |
Recruiting |
NCT06291584 -
Effects of Exercises on Functional Capacity
|
N/A | |
Withdrawn |
NCT06259630 -
Nicotine Virtual Reality Conditioned Place Preference
|
Phase 4 | |
Completed |
NCT02624284 -
tDCS Effects on Resisting Smoking: Dose Ranging Study
|
N/A | |
Active, not recruiting |
NCT02837510 -
Neural Mechanisms Associated With Risk of Smoking Relapse
|
N/A | |
Completed |
NCT02656745 -
Clinical Trial of Smoking Cessation Mobile Phone Program
|
N/A | |
Completed |
NCT01062932 -
Investigation of Cycloserine as a Smoking Cessation Treatment
|
Phase 1 | |
Completed |
NCT03069482 -
Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness
|
Phase 1 | |
Completed |
NCT02870218 -
Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
|
Phase 2 | |
Terminated |
NCT01756053 -
Effects of ABT-089 on Smoking Abstinence Symptoms and Reward
|
Phase 2 | |
Completed |
NCT01252966 -
Cognitive Training for Nicotine Dependence
|
N/A | |
Active, not recruiting |
NCT04946825 -
Quit Smoking Study for People Who Use E-Cigarettes
|
Phase 2 |